A stratified approach to juvenile idiopathic arthritis: leveraging machine learning to uncover subgroups of patients following treatment with etanercept

Clicks: 3
ID: 321683
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #24 of 46 articles by views in Rheumatology Advances in Practice

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives To facilitate a stratified approach to treatment of juvenile idiopathic arthritis (JIA), to uncover trajectory-based patterns of key clinical outcomes following etanercept (ETN) initiation in children and young people (CYP). Methods ETN-naïve CYP with non-systemic JIA recruited to one of three UK, prospective, multicentre cohorts were selected if they started ETN between 2001 and 2019. JADAS71 components (active joint count, physician global assessment (PGA), parent global evaluation (PGE), ESR) were collected in the year following ETN initiation. Clusters of CYP based on JADAS71 component trajectory patterns following ETN initiation were identified using multivariate group-based trajectory models, adjusting for year of ETN initiation. Multinomial logistic regression identified independent predictors of outcome clusters. In a subset of CYP with previously determined MTX trajectories, response clusters were compared descriptively. Results In 1003 CYP, five clusters were identified following ETN initiation. In three clusters, JADAS components changed in parallel: Fast Improvers (16%), Slow Improvers (10%) and Persistent Disease (37%). In two, all components except for one improved over time: Persistent PGA (7%) and Persistent PGE (30%). Where both MTX and ETN trajectories were available (n = 139), 69% of CYP with Persistent Disease following MTX were assigned to other response clusters following ETN initiation. There was high consistency (73%) of CYP having Persistent PGE pattern following both drugs. Conclusions Across multiple disease-modifying anti-rheumatic drugs, JIA disease activity does not always improve to similar degrees across the different features of disease. A majority of CYP initially experiencing Persistent Disease with MTX fall into a response group following ETN.
Reference Key
openalex_W7169800501 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Stephanie J W Shoop-Worrall, Saskia Lawson‐Tovey, L C Wedderburn, Kimme L Hyrich, Nophar Geifman
Journal Rheumatology Advances in Practice
Year 2026
DOI
10.1093/rap/rkag088
URL
https://doi.org/10.1093/rap/rkag088
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.